Published in Diagn Microbiol Infect Dis on September 01, 2000
Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog (2008) 2.80
Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev (2004) 2.45
Self-regulation of Candida albicans population size during GI colonization. PLoS Pathog (2007) 1.85
Inflammation and gastrointestinal Candida colonization. Curr Opin Microbiol (2011) 1.25
Hosting infection: experimental models to assay Candida virulence. Int J Microbiol (2011) 1.14
Gastrointestinal mucins of Fut2-null mice lack terminal fucosylation without affecting colonization by Candida albicans. Glycobiology (2005) 1.06
Intestinal resident yeast Candida glabrata requires Cyb2p-mediated lactate assimilation to adapt in mouse intestine. PLoS One (2011) 1.02
Murine models of Candida gastrointestinal colonization and dissemination. Eukaryot Cell (2013) 0.97
Gastrointestinal Candida colonisation promotes sensitisation against food antigens by affecting the mucosal barrier in mice. Gut (2006) 0.97
Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus. PLoS One (2011) 0.88
Galectin-3 plays an important role in protection against disseminated candidiasis. Med Mycol (2013) 0.85
Competitive Interactions between C. albicans, C. glabrata and C. krusei during Biofilm Formation and Development of Experimental Candidiasis. PLoS One (2015) 0.80
Characterization of Virulence-Related Phenotypes in Candida Species of the CUG Clade. Eukaryot Cell (2015) 0.79
Distinct stages during colonization of the mouse gastrointestinal tract by Candida albicans. Front Microbiol (2015) 0.78
Pathogenic potential of Saccharomyces strains isolated from dietary supplements. PLoS One (2014) 0.76
The game theory of Candida albicans colonization dynamics reveals host status-responsive gene expression. BMC Syst Biol (2016) 0.75
Effect of Antifungal Treatment in a Diet-based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract. Antimicrob Agents Chemother (2016) 0.75
Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies. South Asian J Cancer (2013) 0.75
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother (2007) 3.54
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood (1999) 3.44
A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 3.17
Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol (2001) 2.87
Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis (1999) 2.81
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (1999) 2.74
Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol (2008) 2.57
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother (2004) 2.51
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood (2000) 2.42
Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother (1998) 2.39
Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol (2001) 2.23
Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol (2001) 2.21
Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol (1995) 2.16
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Silent and prolonged Aspergillus DNAemia in oncohematological patients receiving antifungal prophylaxis: a new phenomenon with clinical implications. Bone Marrow Transplant (2010) 2.02
[Prognosis for acute exacerbation of chronic obstructive pulmonary disease in mechanically ventilated patients]. Med Intensiva (2006) 1.97
Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother (2002) 1.87
Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) (1997) 1.83
Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol (1998) 1.81
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Pain during arterial puncture. Chest (1996) 1.79
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood (1999) 1.66
[Esophagitis caused by fluconazole-resistant Candida albicans: therapeutic failure and in vitro correlation]. Med Clin (Barc) (1992) 1.66
Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia (2010) 1.66
Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob Agents Chemother (2005) 1.66
Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood (1991) 1.64
EUCAST technical note on anidulafungin. Clin Microbiol Infect (2011) 1.63
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother (2011) 1.59
Urinary tract infection caused by Corynebacterium group D2: report of 82 cases and review. Rev Infect Dis (1991) 1.56
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2005) 1.55
Treatment of gastric phytobezoars with cellulase. Rev Esp Enferm Dig (1999) 1.55
Influence of body mass index on outcome of the mechanically ventilated patients. Thorax (2010) 1.52
Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol (2012) 1.51
Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob Agents Chemother (2000) 1.50
Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences. Am J Hematol (1993) 1.48
Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS (2007) 1.48
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
[Soft-tissue infection caused by Aeromonas hydrophila]. Enferm Infecc Microbiol Clin (1995) 1.46
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia (2012) 1.45
Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect (2007) 1.43
[Exhaled breath condensate: standardized collection of samples from healthy volunteers]. Arch Bronconeumol (2005) 1.40
How to use sustainability indicators for tourism planning: the case of rural tourism in Andalusia (Spain). Sci Total Environ (2011) 1.39
[Ileal endometriosis as a cause of intestinal obstruction]. Rev Esp Enferm Dig (1998) 1.39
EUCAST technical note on voriconazole and Aspergillus spp. Clin Microbiol Infect (2013) 1.38
EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect (2012) 1.37
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood (1997) 1.33
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother (2000) 1.33
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother (1999) 1.33
Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol (2001) 1.31
Detection of non-milk fat in milk fat by gas chromatography and linear discriminant analysis. J Dairy Sci (2009) 1.31
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia (2013) 1.30
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother (2008) 1.29
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology (2001) 1.28
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol (2012) 1.27
Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia (2005) 1.26
Cystic dysplasia of the testis. Light and electron microscopic study of three cases. Arch Pathol Lab Med (1984) 1.23
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol (2000) 1.23
Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect (2013) 1.23
Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia (2001) 1.22
Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother (2013) 1.22
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J Clin Microbiol (2005) 1.20
Comparison of four molecular typing methods for evaluating genetic diversity among Candida albicans isolates from human immunodeficiency virus-positive patients with oral candidiasis. J Clin Microbiol (1997) 1.19
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant (2012) 1.18
Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood (1998) 1.17
Comparative study of American cutaneous leishmaniasis and diffuse cutaneous leishmaniasis in two strains of inbred mice. Infect Immun (1978) 1.17
Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med (2006) 1.16
Detection of pathogenic fungi in human blood by the polymerase chain reaction. Eur J Clin Microbiol Infect Dis (1995) 1.15
Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur J Clin Microbiol Infect Dis (2001) 1.13
Health education for community-based malaria control: an intervention study in Ecuador, Colombia and Nicaragua. Trop Med Int Health (1996) 1.12
Molecular characterization of acute myeloblastic leukemia according to the new WHO classification: a different distribution in Central-West Spain. Haematologica (2001) 1.12
Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis (2005) 1.11
Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats. Antimicrob Agents Chemother (2001) 1.11
[The rights of the hospital patient: the knowledge and perception of their fulfillment on the part of the professional. The Group in Catalonia of the Spanish Society of Care for the Health Services User]. Rev Clin Esp (1998) 1.10
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica (2001) 1.07
Measurement of general health status of non-oxygen-dependent chronic obstructive pulmonary disease patients. Med Care (1992) 1.07
In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect (2008) 1.05
Bordetella hinzii, a "new" opportunistic pathogen to think about. J Infect (2000) 1.05
In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect (2009) 1.04
Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol (1991) 1.03
Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect (2006) 1.02